Hijacking of the pleiotropic cytokine interferon-γ by the type III secretion system of Yersinia pestis

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Gendrin, Claire ^a   Sarrazin, Stéphane ^a   Bonnaffé, David ^b   Jault, Jean Michel ^a   Lortat Jacob, Hugues ^a   Dessen, Andréa ^a  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; MUTANT PROTEIN; BACTERIAL ANTIGEN; GLUTATHIONE TRANSFERASE; LCRV PROTEIN, YERSINIA; N BROMOSUCCINIMIDE; PORE FORMING CYTOTOXIC PROTEIN;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; IMMUNE SYSTEM; IMMUNOMODULATION; MOLECULAR MECHANICS; NONHUMAN; PLEIOTROPY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TYPE III SECRETION SYSTEM; YERSINIA PESTIS; AMINO ACID SEQUENCE; CELL STRAIN U937; GENETICS; HUMAN; MACROPHAGE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; SEQUENCE HOMOLOGY; SPECTROFLUOROMETRY;

EUKARYOTA; YERSINIA; YERSINIA PESTIS;

AMINO ACID SEQUENCE; ANTIGENS, BACTERIAL; BROMOSUCCINIMIDE; CYTOKINES; GLUTATHIONE TRANSFERASE; HUMANS; INTERFERON-GAMMA; MACROPHAGES; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MUTATION; PORE FORMING CYTOTOXIC PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SPECTROMETRY, FLUORESCENCE; U937 CELLS; YERSINIA PESTIS;

EID: 78650763169     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015242     Document Type: Article

References (54)

1. Perry RD, Fetherston JD (1997) Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10(1): 35-66.
2. Blocker A, Gounon P, Larquet E, Niebuhr K, Cabiaux V, et al. (1999) The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J Cell Biol 147(3): 683-693.
3. Blocker A, Jouihri N, Larquet E, Gounon P, Ebel F, et al. (2001) Structure and composition of the Shigella flexneri "needle complex", a part of its type III secreton. Mol Microbiol 39(3): 652-663.
4. Mueller CA, Broz P, Cornelis GR (2008) The type III secretion system tip complex and translocon. Mol Microbiol 68(5): 1085-1095.
5. Hakansson S, Schesser K, Persson C, Galyov EE, Rosqvist R, et al. (1996) The YopB protein of Yersinia pseudotuberculosis is essential for the translocation of Yop effector proteins across the target cell plasma membrane and displays a contactdependent membrane disrupting activity. EMBO J 15(21): 5812-5823.
6. Schoehn G, Di Guilmi AM, Lemaire D, Attree I, Weissenhorn W, et al. (2003) Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas. EMBO J 22(19): 4957-4967.
7. Faudry E, Vernier G, Neumann E, Forge V, Attree I (2006) Synergistic pore formation by type III toxin translocators of Pseudomonas aeruginosa. Biochemistry 45(26): 8117-8123.
8. Troisfontaines P, Cornelis GR (2005) Type III secretion: more systems than you think. Physiology (Bethesda) 20: 326-339.
9. Quinaud M, Ple S, Job V, Contreras-Martel C, Simorre JP, et al. (2007) Structure of the heterotrimeric complex that regulates type III secretion needle formation. Proc Natl Acad Sci U S A 104(19): 7803-7808.
10. Sun P, Tropea JE, Austin BP, Cherry S, Waugh DS (2008) Structural characterization of the Yersinia pestis type III secretion system needle protein YscF in complex with its heterodimeric chaperone YscE/YscG. J Mol Biol 377(3): 819-830.
11. Brubaker RR (1991) The V antigen of yersiniae: an overview. Contrib Microbio Immun 12: 127-133.
12. Brubaker RR (2003) Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 71(7): 3673-3681.
13. Ramamurthi KS, Schneewind O (2002) Type iii protein secretion in yersinia species. Annu Rev Cell Dev Biol 18: 107-133.
14. Nakajima R, Brubaker RR (1993) Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun 61(1): 23-31.
15. Mueller CA, Broz P, Muller SA, Ringler P, Erne-Brand F, et al. (2005) The Vantigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310(5748): 674-676.
16. Broz P, Mueller CA, Muller SA, Philippsen A, Sorg I, et al. (2007) Function and molecular architecture of the Yersinia injectisome tip complex. Mol Microbiol 65(5): 1311-1320.
17. Motin VL, Nakajima R, Smirnov GB, Brubaker RR (1994) Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 62(10): 4192-4201.
18. Motin VL, Nedialkov YA, Brubaker RR (1996) V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague. Infect Immun 64(10): 4313-4318.
19. Nakajima R, Motin VL, Brubaker RR (1995) Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 63(8): 3021-3029.
20. Nedialkov YA, Motin VL, Brubaker RR (1997) Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect. Immun 65(4): 1196-1203.
21. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75(2): 163-189.
22. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, et al. (1991) Three-dimensional structure of recombinant human interferon-gamma. Science 252(5006): 698-702.
23. Lundell DL, Narula SK (1994) Structural elements required for receptor recognition of human interferon-gamma. Pharmacol Ther 64(1): 1-21.
24. Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, et al. (1995) Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature 376(6537): 230-235.
25. Sadir R, Forest E, Lortat-Jacob H (1998) The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferongamma receptor complex formation. J Biol Chem 273(18): 10919-10925.
26. Lortat-Jacob H, Kleinman HK, Grimaud JA (1991) High-affinity binding of interferon-gamma to a basement membrane complex (matrigel). J Clin Invest 87(3): 878-883.
27. Lortat-Jacob H, Baltzer F, Grimaud JA (1996) Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. J Biol.Chem 271(27): 16139-16143.
28. Abramov VM, Khlebnikov VS, Vasiliev AM, Kosarev IV, Vasilenko RN, et al. (2007) Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor. J Proteome Res 6(6): 2222-2231.
29. Goure J, Broz P, Attree O, Cornelis GR, Attree I (2005) Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J Infect Dis 192(2): 218-225.
30. Sarrazin S, Bonnaffe D, Lubineau A, Lortat-Jacob H (2005) Heparan sulfate mimicry: a synthetic glycoconjugate that recognizes the heparin binding domain of interferon-gamma inhibits the cytokine activity. J Biol Chem 280(45): 37558-37564.
31. Haelewyn J, De Ley M (1995) A rapid single-step purification method for human interferon-gamma from isolated Escherichia coli inclusion bodies. Biochem Mol Bio Int 37(6): 1163-1171.
32. Divita G, Di Pietro A, Roux B, Gautheron DC (1992) Differential nucleotide binding to catalytic and noncatalytic sites and related conformational changes involving alpha/beta-subunit interactions as monitored by sensitive intrinsic fluorescence in Schizosaccharomyces pombe mitochondrial F1. Biochemistry 31(25): 5791-5798.
33. Vanhaverbeke C, Simorre JP, Sadir R, Gans P, Lortat-Jacob H (2004) NMR characterization of the interaction between the C-terminal domain of interferongamma and heparin-derived oligosaccharides. Biochem J 384(Pt 1): 93-99.
34. Heesemann J, Sing A, Trulzsch K (2006) Yersinia's stratagem: targeting innate and adaptive immune defense. Curr Opin Microbiol 9(1): 55-61.
35. Murray PJ (2006a) Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol 6(4): 379-386.
36. Murray PJ (2006b) STAT3-mediated anti-inflammatory signalling. Biochem Soc Trans 34(Pt 6): 1028-1031.
37. Yahr TL, Mende-Mueller LM, Friese MB, Frank DW (1997) Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 179(22): 7165-7168.
38. Nanao M, Ricard-Blum S, Di Guilmi AM, Lemaire D, Lascoux D, et al. (2003) Type III secretion proteins PcrV and PcrG from Pseudomonas aeruginosa form a 1:1 complex through high affinity interactions. BMC Microbiol 3: 21.
39. Broms JE, Sundin C, Francis MS, Forsberg A (2003) Comparative analysis of type III effector translocation by Yersinia pseudotuberculosis expressing native LcrV or PcrV from Pseudomonas aeruginosa. J Infect Dis 188(2): 239-249.
40. Lee PC, Stopford CM, Svenson AG, Rietsch A (2010) Control of effector export by the Pseudomonas aeruginosa type III secretion proteins PcrG and PcrV. Mol Microbiol 75: 924-241.
41. Gebus C, Faudry E, Bohn YS, Elsen S, Attree I (2008) Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis. J Biol Chem 283(35): 23940-23949.
42. Derewenda U, Mateja A, Devedjiev Y, Routzahn KM, Evdokimov AG, et al. (2004) The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague. Structure 12(2): 301-306.
43. Sing A, Roggenkamp A, Geiger AM, Heesemann J (2002) Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice. J Immunol 168(3): 1315-1321.
44. Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, et al. (1999) Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 5(4): 392-398.
45. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, et al. (2002) Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 186(1): 64-73.
46. Fields KA, Nilles ML, Cowan C, Straley SC (1999) Virulence role of V antigen of Yersinia pestis at the bacterial surface. Infect Immun 67(10): 5395-5408.
47. Pettersson J, Holmstrom A, Hill J, Leary S, Frithz-Lindsten E, et al. (1999) The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 32(5): 961-976.
48. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, et al. (2004) The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect Immun 72(8): 4741-4750.
49. Nilles ML, Fields KA, Straley SC (1998) The V antigen of Yersinia pestis regulates Yop vectorial targeting as well as Yop secretion through effects on YopB and LcrG. J Bacteriol 180(13): 3410-3420.
50. Fields KA, Straley SC (1999) LcrV of Yersinia pestis enters infected eukaryotic cells by a virulence plasmid-independent mechanism. Infect Immun 67(9): 4801-4813.
51. Lubineau A, Lortat-Jacob H, Gavard O, Sarrazin S, Bonnaffe D (2004) Synthesis of tailor-made glycoconjugate mimetics of heparan sulfate that bind IFN-gamma in the nanomolar range. Chemistry 10(17): 4265-4282.
52. Nagamatsu K, Kuwae A, Konaka T, Nagai S, Yoshida S, et al. (2009) Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN. J Exp Med 206(13): 3073-3088.
53. Wilson M, Seymour R, Henderson B (1998) Bacterial perturbation of cytokine networks. Infect Immun 66(6): 2401-2409.
54. Arbibe L, Kim DW, Batsche E, Pedron T, Mateescu B, et al. (2007) An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat Immunol 8(1): 47-56.